• Opening of new plasmapheresis centres in the USA, Germany and Hungary
• Consequently, Biotest will operate 20 of its own centres worldwide this year
• Self-sufficiency rate target of 50%

Dreieich, 7 August 2008. Biotest is significantly expanding its capacities for obtaining blood plasma, the raw material used in the production of plasma proteins. The company opened a new plasmapheresis station in Iowa City last week, thus bringing the total number of stations in the USA operated by Biotest to ten. This year, Europe will also see the launch of plasma collection operations at two new centres in Budapest in Hungary and in Nordhausen in Germany.

Including the new openings, Biotest will have 20 of its own plasma collection stations worldwide. Half of these stations are located in the USA and are operated by the US subsidiary Biotest Pharmaceuticals Corporation (BPC). In Germany, Biotest will then have eight centres, in addition to one station in Innsbruck, Austria and one in Budapest, Hungary.

Human blood plasma is the most important raw material used in the production of immunoglobulins, coagulation factors and albumin. By operating its own centres and long-term cooperation with corresponding donors, Biotest is securing a continuous supply of plasma.

At present, the company covers around 40% of its total requirement through its own collection capacities, with this rate set to rise to 50% in the medium term. This high degree of self-sufficiency increases Biotest’s independence from the plasma prices in the global market, which have been recording a continuous upward trend in recent years. The demand for high-value blood plasma will rise further, in particular in immunotherapy, in light of additional areas of application for plasma protein end products.

The process of plasmapheresis involves removing blood plasma from the donor blood while the cellular components (red and white blood cells) are returned immediately to the donor’s circulatory system. In contrast to a whole blood donation, this facilitates a considerably shorter period of time between donations.

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and immunological diagnostics which are used, for example, in blood transfusions and transplants. Biotest has around 1,850 employees worldwide and its shares are listed in the Stock Exchange's SDAX.

---

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth
Tel: +49 (0) 6103 801-338
Fax: +49 (0) 6103 801-347
e-mail: michael_ramroth@biotest.de

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart